AI assistant
EssilorLuxottica — M&A Activity 2010
Jan 22, 2010
1298_iss_2010-01-22_16c1647a-b606-4cf3-98a9-7fbfc22aad40.pdf
M&A Activity
Open in viewerOpens in your device viewer
News Release
Essilor steps up its international development with ten new partnerships
Charenton-le-Pont, France (January 22, 2010 – 6:30 a.m.) – Essilor International has signed ten acquisition or partnership agreements in its five global operating regions since October 2009. These companies generate combined annual revenue of around €35 million.
Two transactions in Europe to strengthen the multi-network strategy
In France, Novisia, an Essilor subsidiary and the exclusive distributor of Nikon lenses in continental Europe, has acquired a majority stake in Mont-Royal, a lens distributor with a prescription laboratory in Goeztenbruck, in the Lorraine region, and annual revenue of around €10 million. The acquisition will strengthen Mont-Royal's market presence while helping to speed Novisia's development in France.
In the UK, the Company has acquired a 95% equity interest in Horizon, a laboratory located in Bedfordshire, north of London, with annual revenue of €3.4 million.
Three transactions in North America to broaden the geographical coverage of the prescription laboratory network
In the United States, Essilor has increased its market share by acquiring a majority or all the interest in three prescription laboratories: Ultimate Optical in Florida, with \$6.3 million in annual revenue, Optical Dimensions in Michigan, with \$3.7 million in annual revenue, and Truckee Meadows Optical in Nevada, with \$3 million in annual revenue.
A third transaction in Latin America
Following its equity investments in the Unilab and Technopark prescription laboratories, the Company has acquired a 51% stake in GBO, a major distributor of finished and semi-finished lenses in Sao Paolo with 2009 revenue of approximately €3 million.
Two transactions in China and India to strengthen Essilor's local market presence
Essilor is expanding its coverage of the Chinese market with the acquisition of an ophthalmic lens manufacturer, Danyang ILT Optics Co. Ltd. The company generates revenue of nearly €7 million in the domestic and export markets.
In India, Essilor has acquired Lens and Spects (€0.45 million in revenue), which comprises a distributor and two prescription laboratories operating in four cities in western India.
Two transactions in the Middle East and Africa to drive growth in new regions
Following its acquisition of an equity interest in Dubai-based Amico, Essilor is pursuing its development in the Middle East. Essilor Amico Middle East FZCo has acquired a majority stake in Ghanada Optical Co. LLC (€1.7 million in revenue), a prescription laboratory located in Abu Dhabi that serves the United Arab Emirates and the Gulf Cooperation Council.
Essilor is strengthening its positions in South Africa with the acquisition of Vision Optics (€0.7 million in revenue), a prescription laboratory based in Durban.
Essilor International is the world leader in ophthalmic optical products, offering a wide range of lenses under the flagship Varilux® , Crizal® , Essilor® , Definity® and Xperio™ brands to correct myopia, hyperopia, astigmatism and presbyopia. Essilor operates worldwide through a broad network of mass-production facilities, lens finishing laboratories and distribution centers.
The Essilor share trades on the NYSE Euronext Paris market and is included in the CAC 40 index. Codes and symbols: ISIN: FR FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.
Investor Relations and Financial Communications Véronique Gillet – Sébastien Leroy Phone: +33 1 49 77 42 16 www.essilor.com